Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women

Clark, P., Twaddle, S., Walker, I.D., Scott, L. and Greer, I.A. (2002) Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women. Lancet, 359(9321), pp. 1919-1920. (doi:10.1016/S0140-6736(02)08740-8) (PMID:12057557)

Full text not currently available from Enlighten.

Abstract

The factor V Leiden (FVL) mutation is associated with vascular complications in pregnancy, and routine screening of all pregnant women has been suggested. We did a prospective, unselected study in 967 pregnant women to evaluate the cost-effectiveness of screening all women, or only those with a personal or family history of venous thrombosis (n=113). When anticoagulant prophylaxis was assumed to effect a 50% reduction in vascular complications, we recorded an additional management cost of UK£3768 with selective screening and £39 841 with universal screening. This additional cost would result in prevention of less than one and three vascular events, respectively. Our findings, therefore, suggest that screening of pregnant women for the FVL mutation is not cost-effective.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Christie, Mrs Linda and Greer, Prof Ian
Authors: Clark, P., Twaddle, S., Walker, I.D., Scott, L., and Greer, I.A.
College/School:College of Medical Veterinary and Life Sciences
College of Social Sciences > School of Social and Political Sciences
Journal Name:Lancet
Publisher:The Lancet Publishing Group
ISSN:0140-6736
ISSN (Online):1474-547X
Published Online:03 June 2002

University Staff: Request a correction | Enlighten Editors: Update this record